Aardvark Therapeutics, Inc. Class Action Lawsuit
Company: Aardvark Therapeutics, Inc.
Ticker: (NASDAQ) AARD
Class Definition: All persons and entities that purchased or otherwise acquired: (a) Aardvark common stock pursuant and/or traceable to the Company’s initial public offering conducted on February 13, 2025; and/or (b) Aardvark securities between February 13, 2025 and May 14, 2026, both dates inclusive.
How to Check Whether You May Be Eligible in the Aardvark Therapeutics, Inc. Class Action
CLASS DEFINITION
All persons and entities that purchased or otherwise acquired: (a) Aardvark common stock pursuant and/or traceable to the Company’s initial public offering conducted on February 13, 2025; and/or (b) Aardvark securities between February 13, 2025 and May 14, 2026, both dates inclusive.
Allegations
The complaint filed against Aardvark Therapeutics, Inc. alleges the company made statements that were materially false and/or misleading and/or failed to disclose that: (i) ARD-101 was less safe than defendants had led investors to believe; (ii) accordingly, ARD-101’s clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, the offering documents were materially false and/or misleading and failed to state information required to be stated therein.
Eligibility
To be eligible for the lawsuit, you need to have suffered a financial loss on Aardvark Therapeutics, Inc. shares that were bought or otherwise acquired during the class period noted above and/or in connection with the stock offering(s) mentioned above.
Lead Plaintiff Deadline
If you suffered a loss in Aardvark Therapeutics, Inc. during the relevant time frame, you have until October 13, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Frequently Asked Questions
- How can Aardvark Therapeutics, Inc. (NASDAQ: AARD) investors check whether their transactions may be relevant?
Investors whose purchases or acquisitions of Aardvark Therapeutics, Inc. securities fall within the proposed class definition described above may submit their transaction details through this case page.
- Ensure your purchase falls within the class period
- Provide basic transaction and loss details
- Submit your information for review
The lead plaintiff deadline for this case is October 13, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. No action is required before this date to remain a potential class member.
- Who may be eligible for the Aardvark Therapeutics, Inc. lawsuit?
Investors whose purchases or acquisitions of Aardvark Therapeutics, Inc. securities fall within the proposed class definition described above and who suffered financial losses may be eligible.
- Could I still be eligible for the Aardvark Therapeutics, Inc. lawsuit if I sold my shares?
Yes. Investors whose purchases or acquisitions fall within the proposed class definition may still be eligible even if they later sold their shares.
- How much compensation could I receive from the Aardvark Therapeutics, Inc. lawsuit?
Any potential compensation would depend on the outcome of the case, the applicable class definition, and any settlement or judgment. If there is a recovery, eligible investors may receive a portion of it.
- What documents may be required for the Aardvark Therapeutics, Inc. lawsuit?
Investors may be asked to provide transaction records, purchase and sale dates, number of shares, and loss details.
- Will I need to appear in court for the Aardvark Therapeutics, Inc. lawsuit?
In most cases, investors do not need to appear in court. Whether an investor may need to participate personally depends on their role and developments in the case.
EXPLORE MORE CASES
Wise Group plc
WSE
Wise Group plc WSE Securities Class Action Lawsuit Update
Lead Plaintiff Deadline: September 29, 2026
Class Period: May 11, 2026 - July 23, 2026
Avis Budget Group, Inc.
CAR
Lead Plaintiff Deadline: September 29, 2026
Class Period: February 20, 2026 - April 21, 2026